Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...

Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...

In a press release, drug giant Eli Lilly announced that it's releasing single-dose vials of tirzepatide, the active ingredient in Zepbound and its diabetes sister drug Mounjaro, that customers ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...

Glucagon-like peptide-1 (GLP-1) agonists such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are becoming ever more popular among diabetes and obesity care patients. Let's dig into Lilly's ...

Drugmaker Eli Lilly is lowering the prices of the two lowest doses of its weight loss drug Zepbound, but they won't be ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ... the company for comment. Eli Lilly, the manufacturer of tirzepatide ...

Eli Lilly & Co. is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399 a month as it works to overcome supply shortages of wildly popular shots.

Lilly has started selling vials of the lowest dose of Zepbound in U.S. through its direct-to-consumer website to improve availability and combat the rise in popularity of compounded versions.

Let's dig into Lilly's latest move concerning Zepbound, its blockbuster drug for chronic weight management, and assess why now could be a lucrative time to scoop up some shares. Although GLP-1 ...